Sandbox Reserved 1052: Difference between revisions

No edit summary
No edit summary
 
(28 intermediate revisions by 4 users not shown)
Line 1: Line 1:
==Ag85C of ''Mycobacterium tuberculosis''==
'''Bold text'''<Structure load='2KJB' size='350' frame='true' align='left' caption='3D Representation of CzrA with Zn Bound' scene='Insert optional scene name here' />
<StructureSection load='1dqz' size='340' side='right' caption='Caption for this structure' scene=''>
== Background ==
[https://en.wikipedia.org/wiki/Operon Operons] are a critical genetic component of most prokaryotic cells. There are many different operons that are responsible for the production of proteins with a wide range of functions, the most well-known of which are the Lac and Trp operons, responsible for producing enzymes which metabolize lactose and tryptophan respectively. Despite many differences in each operon and the proteins that they encode, operons all function in the same general manner. Structurally, each operon contains a regulator, an operator, and one or more structural genes. The regulator protein is responsible for managing the expression level of the structural genes, the operator is similar to a promoter in a regular gene and is where transcription begins, and the structural genes code for proteins. The regulator protein (produced as a result of expression of the regulator gene) most often acts in a repressive manner, though this is not always the case. That is, the regulator protein will bind to the operator of the operon, inhibiting the binding and/or progression of [https://en.wikipedia.org/wiki/RNA_polymerase RNA polymerase] to the structural genes, thus inhibiting transcription of the genes into mRNA.  If the regulator protein were to consistently be active, there could never be adequate expression of the structural genes, so there must be a way to inactive the regulator protein, thus enabling expression of the structural genes. This is achieved through the binding of an inhibitor to the regulator protein. Since regulator proteins are DNA binding proteins, often this inhibition is allosteric rather than competitive, that is the inhibitor is not something that mimics DNA and binds to the active site physically blocking DNA from binding. Rather, the inhibitor of the regulator binds to somewhere other than the active site of the protein, changing it in some way which decreases the proteins affinity or ability to bind DNA. The Chromosome Determined Zinc Responsible (Czr) operon acts in exactly this manner, Czr A specifically is the regulator protein. The role of Czr A in the Czr operon is described in further detail under biological function.
In addition to being a component of an operon, Czr A is also considered to be a metal sensor protein. While the immediate function of Czr A is gene regulation, this serves the larger purpose of acting to maintain an appropriate concentration of Zn <sup>2+</sup> in the cell.


== '''Introduction''' ==
[[Image:Operon.png|600px|thumb|center|Visual of Overview of Operon Structure]]
[[Image:AG85C homodimer.jpg |100 xp|left|thumb|'''Figure 1.'''  Ag85C homodimer. ]]  
[http://en.wikipedia.org/wiki/Mycobacterium_tuberculosis ''Mycobacterium tuberculosis''] is the bacteria that causes the [http://www.mayoclinic.org/diseases-conditions/tuberculosis/basics/definition/con-20021761 tuberculosis] (TB) disease itself, a leading infectious cause of death world-wide.  Thus, it is necessary to develop antimycobacterial drugs.  However, this has proven to be difficult as the bacteria can become resistant as a result of misuse of drugs.  This gives the bacteria time to mutate which ultimately leads to the drug resistance. To combat this, scientists and researchers have taken on many studies and clinical trials to locate specific drug targets. Obstacles for controlling TB infection include lengthy treatment regimens, drug resistance, lack of a highly efficacious vaccine, and incomplete understanding of the factors that control virulence and disease progression.<ref> Online Mendelian Inheritance in Man (OMIM). Mycobacterium tuberculosis, susceptibility to. [Internet]. Baltimore (MD): Johns Hopkins University; 2014 Nov 12 [cited 2015 March 16]. Available from http://www.omim.org/entry/607948 </ref>  Of these projects, some deal specifically with the ''M. tuberculosis'' [http://onlinelibrary.wiley.com/doi/10.1046/j.1472-765x.2002.01091.x/epdf Antigen 85] (Ag85) complex.  Ag85 complex consists of 3 secreted enzymes (A, B, and C) and plays a key role in pathogenesis and cell wall synthesis of ''M. tuberculosis''. <ref name="Favrot"/>
== Structure Testing Area ==
<Structure load='CzrAwithDNA.pdb' size='350' frame='true' align='right' caption='Insert caption here' scene='Insert optional scene name here' />


The [http://www.hindawi.com/journals/jir/2011/405310.fig.001.jpg cell wall of mycobacterium tuberculosis] covalently linked molecules, one of which is [https://en.wikipedia.org/wiki/Mycolic_acid mycolic acid], a fatty acid which exists in the membrane as the free glycolipids trehalose monomycolate (TMM) and [http://en.wikipedia.org/wiki/Trehalose_dimycolate trehalose dimycolate] (TDM). Studies suggest that these three components are necessary to maintain the integrity of the cell wall.<ref name="Gobec">PMID:15177473</ref>  More specifically, Ag85C is important in the generation of the bacterial cell wall in that it transfers the necessary mycolic acid to the rest of the Ag85 complex, and thus it is suggested that the enzyme displays mycolyltransferace activity.  Specifically, the Ag85 enzymes catalyze the transfer of a mycolyl residue from one molecule of α, α-trehalose monomycolate (TMM) to another TMM, leading to the [http://biology.kenyon.edu/BMB/Jmol2009/KatandSuzanne/TDM-Formation.jpg formation of TDM].  Trehalose is necessary for proper growth of the bacterial cells. Thus, there is potential to target these enzymes with specific drugs to prevent the spread of the disease.<ref name="Favrot"/>


 
== Biological Function ==
== '''Clinical Relevance''' ==
Czr A is a transcriptional repressor protein responsible for the regulation of the Czr operon<ref name="critical">Arunkumar A., Campanello G., Giedroc D. (2009). Solution Structure of a  
Because the cell wall envelope of ''M. tuberculosis'' is essential for the bacteria’s viability and virulence, it is the primary target for antimycobacterial drugs. More specifically, it is known that the Ag85 complex with its three protein components (A, B, and C) plays a key role in cell wall biosynthesis and the [http://www.nature.com/nchembio/journal/v7/n4/images_article/nchembio.539-F1.jpg transfer of mycolic acid from one molecule of TMM to another]. The resultant molecule, TDM, has been suggested to be important in maintaining ''M. tuberculosis'' cell wall integrity.  Studies have also suggested that removal of Ag85C from a strain of ''M. tuberculosis'' results in a significant decrease in the presence of cell-wall linked mycolic acids. Thus, scientists hypothesize that inhibition of Ag85C and its mycolyltransferase activity will disrupt TDM and its ability to maintain cell wall integrity.<ref name="Gobec"/> Knowing this, researchers have suggested that inhibition of mycolic acid transfer and, ultimately, Ag85C, must be involved in the continuously-developing class of antimycobacterial drugs aimed at combatting ''M. tuberculosis''.<ref>PMID:9162010</ref>
paradigm ArsR family zinc sensor in the DNA-bound state. PNAS 106:43
 
18177-18182.</ref>. The Czr operon contains genes for the proteins Czr A and [http://proteopedia.org/wiki/index.php/3byr Czr B]. Czr B is a Zinc transport protein which moves Zn<sup>2+</sup> out of a cell while Czr A regulates this process by controlling expression level of Czr B. When relatively low amounts of zinc are present in the cell Czr A will bind to DNA, preventing the progression of RNA polymerase and thus inhibiting expression of Czr B. Decreased expression of Czr B results in the ability of the cell to retain Zn<sup>2+</sup> more readily. Because Czr A and Czr B are transcribed as part of the same operon, an inhibitor of Czr A must be readily available to allow full transcription of Czr B when necessary. Czr A is noncompetitively inhibited by the binding of two Zn<sup>2+</sup> ions, which is ideal in that this allows for expression of Czr B, a Zn<sup>2+</sup> transporter to be dependent on the relative amount of Zn<sup>2+</sup> in the cell.  Czr A displays two different conformations; the first typically binds DNA and has relatively low affinity for Zn<sup>2+</sup>, in this conformation the <scene name='69/694220/A5_helices__dna_binding/1'>a5 helices are open</scene>. The <scene name='69/694220/A5_helices_dna_binding/1'>a5 helices swing down</scene> to achieve the other conformation which binds two Zn<sup>2+</sup> ions and has relatively low affinity for DNA.   
 
===DNA Binding ===
== '''Structure''' ==
Czr A performs it's primary function when bound to DNA<ref name="critical"/>. Each monomeric subunit of the protein binds DNA individually, coming together once attached to the DNA. While bound, Czr A prevents the transcription of the DNA in the Czr operon, acting as a repressor protein and effectively turning off the operon. As was briefly mentioned above, the Czr operon contains the gene responsible for producing Czr B, a metal transport protein which regulates the concentration of zinc in the cell. So, by extension, Czr A is responsible for retaining Zn<sup>2+</sup> inside the cell by inhibiting the production of the protein responsible for transporting zinc out of the cell.
Ag85 C is a <scene name='69/694219/Dimer/1'>dimer</scene> of identical subunits (Figure 1), and quite a bit about the amino acid sequence and overall structure of Ag85C is knownThe enzyme contains a [http://en.wikipedia.org/wiki/Catalytic_triad catalytic triad] comprised of [http://en.wikipedia.org/wiki/Serine serine], [http://en.wikipedia.org/wiki/Glutamic_acid glutamate], and [http://en.wikipedia.org/wiki/Histidine histidine].
===Zinc Binding ===
This would lead us to think that we could inhibit mycolyl transfer and shut down the enzyme by directly inhibiting the serine residue of the <scene name='69/694218/Catalytic_triad/2'>catalytic triad</scene>, but we can instead modify a near by [http://en.wikipedia.org/wiki/Cysteine cysteine] residue and have the same effect.  This was determined by a series of experiments in which scientists generated various mutants and modifications of the Ag85C enzyme.<ref> Research Collaboratory for Structural Bioinformatics Protein Database (RCSB PDB) Diacylglycerol acyltransferase/mycolyltransferase Ag85C - P9WQN9 (A85C_MYCTU). [Internet] San Diego (CA): University of San Diego; 2014 [cited 2015 March 16]. [http://dx.doi.org/10.2210/pdbp9wqn9/pdb DOI:10.2210/pdbp9wqn9/pdb]</ref>
Zinc acts as an inhibitor to Czr A<ref name="critical"/>, thus preventing transcriptional repression of Czr B and allowing Zn<sup>2+</sup> transport out of the cell. This allows for zinc transport to essentially be self regulated. That is, when zinc concentration in the cell is relatively high, zinc ions bind to Czr A, causing a conformational change which releases the bound DNA. DNA without Czr A bound is free to be transcribed and Czr B is again expressed, allowing for Zn<sup>2+</sup> transport out of the cell.  
 
===Active Site===
== Structural Overview ==
[[Image:AG85C active site 3.jpg |100 xp|left|thumb|'''Figure 2.'''Ag85C with labeled active site residues. The three catalytic residues, Ser124, Glu228, and His260, as well as Cys209 are labeled.]] Within the <scene name='69/697503/Active_site/2'>Ag85C active site</scene>,the homodimers shown in blue and green and the active site shown in white, three residues function together to make up the <scene name='69/694219/Cattri/1'>catalytic triad</scene> for this enzyme (Figure 2).  The goal of the catalytic triad is to generate a nucleophilic residue for covalent catalysis by using an acid-base-nucleophile triad.  These three residues, Ser124, Glu228, and His260 form a charge-relay network to polarize and activate the nucleophile, Ser124, which is then able to attack the substrate to form a covalent intermediate, which is then hydrolysed to regenerate a free enzyme. This charge relay is an example of the well known [http://en.wikipedia.org/wiki/Chymotrypsin chymotrypsin mechanism]. Overall, it is suggested that increased enzymatic activity is attributed to the components of the active site remaining intact so that the serine nucleophile can react to form an intermediary and stabilize the transition state formed during catalysis. In the native structure, the <scene name='69/694219/Helix/2'>α-helix 9</scene> maintains a kinked conformation necessary for correct formation of the hydrogen bonding network between the residues of the catalytic triad, thus allowing for high enzymatic activity.<ref name="Favrot"/>
CzrA functions as a [https://en.wikipedia.org/wiki/Dimer_(chemistry) dimer]. The <scene name='69/694218/Monomeric_unit/1'>monomeric units</scene> dimerize at the czr operon, repressing gene transcription. Each monomeric unit contains <scene name='69/694218/Helices/1'>five alpha helices</scene> seen in purple and <scene name='69/694218/B_sheets/1'>two beta sheets</scene> displayed in yellow. While the function of the [https://en.wikipedia.org/wiki/Beta_sheet beta sheets] are not yet known, key [https://en.wikipedia.org/wiki/Alpha_helix helices] regulate the binding of DNA and Zn<sup> +2 </sup>. The <scene name='69/694218/Alpha_4_helix/1'>alpha 4 helix</scene> is the location of DNA binding and the <scene name='69/694218/Alpha_5_helix/1'>alpha 5 helix</scene> contains the Zn<sup> +2 </sup> binding site. As Zn<sup> +2 </sup> binds, the alpha 4 helices are <scene name='69/694218/Alpha_4_helices_pushed/1'>pushed out of alignment</scene>, repressing their DNA binding ability.
 
===Cysteine 209===
== Binding of DNA ==
<scene name='69/694218/Cysteine_209/2'>Cysteine 209</scene> is located near the <scene name='69/697503/Active_site/2'>Ag85C active site</scene>, but is not directly involved in the enzyme mechanism. Recent studies suggest that this residue plays a significant role in the deactivation of Ag85C, using a mechanism not previously considered for these enzymes.  Any mutation or modification to the Cys209 residue results in the relaxation of the otherwise kicked α-helix 9, which disrupts the hydrogen bonding network within the catalytic triad of the enzyme and inactivates Ag85C.<ref name="Favrot"/>
The <scene name='69/694219/Serandhisresidues/2'>main DNA interactions</scene> have been found to occur at the Ser 54 and 57 along with His 58 residues. These residues are likely to interact with the 5'-TGAA sequence found in the half-site of the DNA. The alpha 4 helices <scene name='69/694219/Czra_with_dna/2'>form an interaction with DNA</scene>. These residues are found in the N terminal of the R helix. The residues involved in the <scene name='69/694219/Dna_binding_pocket/1'>DNA binding pocket</scene> are Val 42 and Gln 53. This was experimentally determined by mutating the Gln and Val with Ala residues and measuring the binding capacity; In a previously published article <ref name="critical"/>, the DNA bound state of CzrA was tested by using the known critical residues for DNA interactions. Critical residues, Gln53, Val42, Ser54, Ser57, and His58, were replaced with Ala and then compared to the kinetics of the wild type protein. Replacing only the Q53 and V42 residues resulted in an 11-fold and 160-fold decrease in K<sub>a</sub>, respectively. Other residues such as S54, S57, and H58 were also replaced with Ala residues, and it was found that these mutations caused binding similar to the fully inhibited Zn<sup>2+</sup> bound state. Table 1 in this same article shows the different K<sub>observed</sub>, and the measured decrease in K<sub>observed</sub> for each mutation. The bind between the DNA and the protein can be attributed to losing certain intermolecular forces such as possible hydrogen bonding when changing from Gln and Ala, and a loss of London Dispersion forces in the Val to Ala change. [[Image:Capture01.PNG|300px|center|thumb| Comparison of Val, Ala, and Gln residues]]
 
 
The differences in binding favorability can also be seen when comparing the ΔG for the Apo-state vs. the DNA bound state and the Zinc vs. the Zinc and DNA bound state. These ΔGs were found to be -15.2kcal/mol and -9kcal/mol respectively<ref>DOI: 10.1021/ja208047b</ref>. This agrees with previously published data showing the Zinc binding inhibits the affinity the protein has to DNA.
=='''Mutations and Modifications'''==
Researchers hold particular interest in specific geometric restraints caused by ligands introduced in various Ag85C mutants and modifications: <scene name='69/694218/Ag85c-ebselen/1'>Ag85C-Ebselen</scene>, <scene name='69/694218/Ag85c-hg/1'>Ag85C-Hg</scene>, <scene name='69/694218/Ag85c-e228q/1'>Ag85C-E228Q</scene>, and <scene name='69/694218/Mutationh260q/1'>Ag85C-H260Q</scene>. Other mutants and modifications not described here include [http://proteopedia.org/wiki/index.php/4qdt Ag85C-IAA], [http://proteopedia.org/wiki/index.php/4qdx Ag85C-C209G], and [http://proteopedia.org/wiki/index.php/4qek Ag85C-S124A]. The results demonstrate that modification of Ag85C by [http://en.wikipedia.org/wiki/Thiol thiol]-reactive compounds imparts structural changes in the enzyme’s active site. Specifically, scientists note a disruption in the natural kink in helix α-9.  The resulting relaxed conformation of the helix significantly reduces or completely eliminates the enzymatic function of Ag85C.<ref name="Favrot"/>
 
== Zinc Binding ==
===Ag85C-ebselen===
Most zinc-dependent proteins are transcriptional regulators<ref>DOI: 10.1128/MMBR.00015-06</ref>. CzrA fits into this category as an [https://en.wikipedia.org/wiki/Allosteric_regulation allosteric inhibitor] of the czr operon. Two [https://en.wikipedia.org/wiki/Zinc Zn<sup> +2</sup>] ions may bind to the dimer<ref name="critical"/>, at the location of the <scene name='69/694218/Alpha_5_helices/2'> alpha 5 </scene> helix from each monomer. As zinc binds, the alpha 5 helices <scene name='69/694218/2kjc_zinc_bound/1'>swing down</scene> to inhibit the DNA binding residues. Furthermore, CzrA must be in its dimer form for zinc to bind. The <scene name='69/694218/Spacefill_with_zinc_pockets/1'>zinc binding pocket</scene> is formed by two residues from each monomer, so Zn<sup>+2</sup> cannot bind to the monomer. The <scene name='69/694218/Zinc_residues/1'>zinc binding site</scene> is formed by Asp84 and His86 from one monomer, and His97 and His100 from the other monomer. Histidines are a repetitive and commonly found residue in zinc-binding proteins <ref>Miller J, McLachlan AD, Klug A. Repetitive zinc-binding domains in the protein transcription factor IIIA from Xenopus oocytes. EMBO J. 1985 Jun 4;4(6):1609-1614.</ref>.
[[Image:Ag85 ebselen.jpg |100 xp|left|thumb|'''Figure 3.''' [http://proteopedia.org/wiki/index.php/4qdu Ag85C-ebselen]: Ebselen covalently binds to Cys209 and forces the otherwise kinked helix α-9 to take on a relaxed conformation, thus allowing movement of the helix and a reduction in enzymatic activity.  The native structure is shown in blue while the modified version is shown in purple, demonstrating a relaxed helix. Ebselen-bound Cys209 is shown in green.]]
   
 
Zinc<sup>+2</sup> binding is driven by a large [https://en.wikipedia.org/wiki/Entropy entropic] gain <ref>DOI:10.1021/ja906131b</ref>. Water molecules around the metal ion and CzrA protein are displaced, and gain greater freedom. This gain in entropy allows Zn<sup>+2</sup> to bind to CzrA with reasonable affinity and speed in vivo. The zinc<sup>+2</sup> ion forms a tetrahedral complex with the four residues (Figure 1). This allows other metal ions to act as allosteric inhibitors to CzrA. Any metal that may form a tetrahedral complex will have some affinity for CzrA, assuming it is not too large to fit into the pocket. However, the metal binding pocket of CzrA has been optimized  to bind Zn<sup>+2</sup> with the highest affinity. As CzrA is a transcriptional repressor, binding of Zn<sup>+2</sup> to the dimer will activate the czr operon. Zn<sup>+2</sup> is preferred as CzrB opens a Zn<sup>+2</sup> channel, allowing the excess zinc ions to export the cell.
[[Image:ebselen pic.jpg |100 xp|right|thumb|'''Figure 4.''' Ebselen.]]
[[Image:Zinc tetrahedral complex.PNG|thumb|center| Figure 1:Zn<sup>+2</sup> tetrahedral binding complex]]
 
<scene name='69/694218/Ebselen/1'>Ag85C-Ebselen</scene> (Figure 3) is characterized by a covalent bond between [http://en.wikipedia.org/wiki/Ebselen ebselen](figure 4) and Cys209, thus forcing the otherwise kinked helix α-9 to take on a relaxed conformation (Figure 3). This [http://www.jbc.org/content/289/36/25031/F4.expansion.html alteration of Cys209] allows movement of the helix and causes disruption of the hydrogen bonds within the catalytic triad, ultimately inactivating Ag85C.<ref name="Favrot"/>
 
These initial findings suggest that ebselen-like mutants characterized by alterations in Cys209 may serve as potential drug targets for ''M. tuberculosis''. Because any modification or mutation of Cys209 in Ag85C leads to either a dramatic decrease or complete loss of enzymatic activity, research suggests there is a low probability of ''M. tuberculosis'' developing resistance to a drug modifying the Cys209The structures and results of the following mutations and modifications support a strategy for inhibiting the Ag85 complex as a whole with mechanism-based inhibitors that first react with Ser124 to promote the relaxation of helix α-9 and expose Cys209 and then react with Cys209 side chain thiol to <scene name='69/694218/Ebselen/2'>covalently modify this conserved residue</scene>. Such a bifunctional inhibitor would offer specificity while minimizing the probability of selecting for drug resistant mutants.<ref name="Favrot"/>
 
{{clear}}
 
===Ag85C-Hg===
 
[[Image:ag85c Hg zoom.png|100 xp|left|thumb|'''Figure 5.''' [http://proteopedia.org/wiki/index.php/4qdo Ag85C-Hg] active site. Glu228 and His260 are shown in red.  The addition of p-chloromercuribenzoic acid disrupts the hydrogen bond between the two resides, causing a change in the helix conformation of this modified structure. The native structure is shown in green and the relaxed, modified structure is shown in blue.]]
 
 
[[Image:P-chloromercuribenzoic acid.jpg |100 xp|right|thumb|'''Figure 6.''' p-chloromercuribenzoic acid]]
 
 
The mutant [http://proteopedia.org/wiki/index.php/4qdo Ag85C-Hg] is generated with the addition of [http://en.wikipedia.org/wiki/4-Chloromercuribenzoic_acid p-chloromercuribenzoic acid] (Figure 6), the side chain of the complex is disordered due to a lack of hydrogen bonds between Glu228 and His260.  Similar to what is observed in Ag85C-ebselen, the alteration in <scene name='69/694218/4qdo/1'>Ag85C-Hg</scene> relaxes the kinked helix α-9 found in the native structure of the enzyme, thus inhibiting the active site (Figure 5).  The ultimate effect is a decrease to only 60% of the normal enzymatic function of Ag85C.<ref name="Favrot"/>
 
{{clear}}
 
===Ag85C-E228Q===
 
 
[[Image:E228Q zoom.png |100 xp|left|thumb|'''Figure 7.''' [http://proteopedia.org/wiki/index.php/4qdz Ag85C-E228Q] active site.  The glutamate residue is shifted four angstroms in the mutated form of this enzyme causing a rearrangement of hydrogen bonds within the enzyme. The histidine residue, labeled in pink, takes on two conformations, binding with alternative serine residues, labeled in red.]]
 
The mutation introduced in [http://proteopedia.org/wiki/index.php/4qdz Ag85C-E228Q]causes the Glu228 of the catalytic triad to be shifted 4 angstroms from its original position in the native structure of Ag85C (Figure 7). Due to the shift of Glu228 is the loss of hydrogen bonds between Ser124 and His260.  Instead, <scene name='69/694218/4qdz/2'>His260 bonds with Ser148</scene>, which also results from the shift of Glu228.  A weak electron density difference in the His260 position of the native and mutated structures was also noted, suggesting that the residue may take on two alternative conformations in the <scene name='69/694218/Ag85c-e228q/1'>Ag85C-E228Q</scene> mutant.  Overall, the enzyme functionality is decreased to only 17% activity.<ref name="Favrot"/>
 
Unlike other Ag85C mutants and modifications aforementioned, the <scene name='69/694218/Ag85c-e228q/1'>Ag85C-E228Q</scene>does not eliminate any hydrogen bonds in the catalytic triad.  Rather, it simply replaces a carboxylate moiety with an amide.  Further, the structural change observed in the low-energy conformation of the <scene name='69/694218/Ag85c-e228q/1'>Ag85C-E228Q</scene> mutant provides additional support for the hypothesis that the natively kinked helix α-9 is central to the enzymatic function of Ag85C.<ref name="Favrot"/>
 
{{clear}}
 
===Ag85C-H260Q===
 
[[Image:H260Q zoom.png|100 xp|left|thumb|'''Figure 8.''' [http://proteopedia.org/wiki/index.php/4qe3 Ag85C-H260Q] active site.  A shift in helix α-9 prevents formation of any stabilizing hydrogen bonds between residues His260 and Glu228, thus decreasing its enzymatic activity.]]
 
In <scene name='69/694218/Mutationh260q/1'>Ag85C-H260Q</scene>, a shift in helix α-9 <scene name='69/694218/Ag85c-hg/1'>prevents the hydrogen bond formation</scene>between residues His260 and Glu228, thus decreasing its enzymatic activity (Figure 8).  The conversion of the glutamate, a key player in the catalytic triad, to the corresponding amide-containing side chain as well as a loss of a general base in the charge relay are both key causes for the loss of function.<ref name="Favrot"/>
 
</StructureSection>
== References ==
== References ==
<references/>
<references/>

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA, Morgan Blake, Sarah Zimmerman, Geoffrey C. Hoops, Mary Liggett, Jakob Jozwiakowski